Skip to main content

Live-Cell Imaging of Protease Activity: Assays to Screen Therapeutic Approaches

  • Protocol
  • First Online:
Protein Terminal Profiling

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1574))

Abstract

Methodologies to image and quantify the activity of proteolytic enzymes have been developed in an effort to identify protease-related druggable pathways that are involved in malignant progression of cancer. Our laboratory has pioneered techniques for functional live-cell imaging of protease activity in pathomimetic avatars for breast cancer. We analyze proteolysis in the context of proliferation and formation of structures by tumor cells in 3-D cultures over time (4D). In order to recapitulate the cellular composition and architecture of tumors in the pathomimetic avatars, we include other tumor-associated cells (e.g., fibroblasts, myoepithelial cells, microvascular endothelial cells). We also model noncellular aspects of the tumor microenvironment such as acidic pericellular pH. Use of pathomimetic avatars in concert with various types of imaging probes has allowed us to image, quantify, and follow the dynamics of proteolysis in the tumor microenvironment and to test interventions that impact directly or indirectly on proteolytic pathways. To facilitate use of the pathomimetic avatars for screening of therapeutic modalities, we have designed and fabricated custom 3D culture chambers with multiple wells that are either individual or connected by a channel to allow cells to migrate between wells. Optical glass microscope slides underneath an acrylic plate allow the cultures to be imaged with an inverted microscope. Fluid ports in the acrylic plate are at a level above the 3D cultures to allow introduction of culture media and test agents such as drugs into the wells and the harvesting of media conditioned by the cultures for immunochemical and biochemical analyses. We are using the pathomimetic avatars to identify druggable pathways, screen drug and natural product libraries and accelerate entry of validated drugs or natural products into clinical trials.

$These authors contributed equally to this work.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Edwards D, Høyer-Hansen G, Blasi F, Sloane BF (2008) The cancer degradome: proteases and cancer biology. Springer-Verlag, New York

    Book  Google Scholar 

  2. Sloane BF, List K, Fingleton B, Matrisian L (2013) Proteases in cancer—significance for invasion and metastasis. In: Brix K, Stoecker W (eds) Proteases—structure and function. Springer-Verlag Wien, Vienna, pp 491–550

    Google Scholar 

  3. Lopez-Otin C, Matrisian LM (2007) Emerging roles of proteases in tumour suppression. Nat Rev Cancer 7(10):800–808

    Article  CAS  PubMed  Google Scholar 

  4. Lopez-Otin C, Bond JS (2008) Proteases: multifunctional enzymes in life and disease. J Biol Chem 283(45):30433–30437

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Schwartz DR, Moin K, Yao B, Matrisian LM, Coussens LM, Bugge TH, Fingleton B, Acuff HB, Sinnamon M, Nassar H, Platts AE, Krawetz SA, Linebaugh BE, Sloane BF (2007) Hu/Mu ProtIn oligonucleotide microarray: dual-species array for profiling protease and protease inhibitor gene expression in tumors and their microenvironment. Mol Cancer Res 5(5):443–454

    Article  CAS  PubMed  Google Scholar 

  6. Kappelhoff R, Auf dem Keller U, Overall CM (2010) Analysis of the degradome with the CLIP-CHIP microarray. Methods Mol Biol 622:175–193

    Article  CAS  PubMed  Google Scholar 

  7. Acuff HB, Sinnamon M, Fingleton B, Boone B, Levy SE, Chen X, Pozzi A, Carbone DP, Schwartz DR, Moin K, Sloane BF, Matrisian LM (2006) Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer. Cancer Res 66(16):7968–7975

    Article  CAS  PubMed  Google Scholar 

  8. Jedeszko C, Sameni M, Olive MB, Moin K, Sloane BF. 2008 Visualizing protease activity in living cells: from two dimensions to four dimensions. Curr Protoc Cell Biol Chapter 4:Unit 4.20.

    Google Scholar 

  9. Sameni M, Tovar EA, Essenburg CJ, Chalasani A, Linklater ES, Borgman A, Cherba DM, Anbalagan A, Winn ME, Graveel CR, Sloane BF (2016) Cabozantinib (XL184) inhibits growth and invasion of preclinical TNBC models. Clin Cancer Res 22(4):923–934

    Article  CAS  PubMed  Google Scholar 

  10. Ramalho SD, Sharma R, White JK, Aggarwal N, Chalasani A, Sameni M, Moin K, Vieira PC, Turro C, Kodanko JJ, Sloane BF (2015) Imaging sites of inhibition of proteolysis in pathomimetic human breast cancer cultures by light-activated ruthenium compound. PLoS One 10(11):e0142527

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgment

We would like to thank members of the Sloane laboratory for their discussions and contributions to the development of pathomimetic avatars and Dr. Yong Xu’s lab for fabrication of TAME chambers. This work was supported in part by R01 CA131990 and R21 CA175931 from the National Institutes of Health to Dr. Sloane and an award from the President’s Research Enhancement Program of Wayne State University to Drs. Sloane and Xu. Imaging was performed in the Microscopy, Imaging and Cytometry Resources Core, which is supported, in part, by NIH Center grant P30 CA022453 to the Karmanos Cancer Institute at Wayne State University, and the Perinatology Research Branch of the National Institutes of Child Health and Development at Wayne State University.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Bonnie F. Sloane .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media LLC

About this protocol

Cite this protocol

Chalasani$, A. et al. (2017). Live-Cell Imaging of Protease Activity: Assays to Screen Therapeutic Approaches. In: Schilling, O. (eds) Protein Terminal Profiling. Methods in Molecular Biology, vol 1574. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6850-3_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-6850-3_16

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-6849-7

  • Online ISBN: 978-1-4939-6850-3

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics